Verdiva's CEO Khurem Farooq emphasized, "People living with obesity and its complications deserve better options at each stage of their treatment journey..." making a case for improved treatment alternatives.
The company's approach to developing an oral-based GLP-1 drug, which curbs hunger, highlights its aim to provide less invasive and more accessible options for weight management.
The rise in global spending on anti-obesity medications is set to exceed $30bn for the first time in 2024, reflecting a significant shift in the pharmaceutical landscape.
Farooq noted that existing weight loss drugs leave "significant medical needs" unmet, demonstrating the urgent need for innovative solutions in obesity treatment.
Collection
[
|
...
]